Open an account

Prime Medicine

PRME · NASDAQ

$3.92+$0.09 (+2.35%)TodayMarket closed ·
Prev close $3.83

About PRME

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2022-10-20. The company deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. The company is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.

Employees
146
Headquarters
Cambridge, Massachusetts
Listed
Oct 20, 2022
Sector
Health Care
Industry
Biotechnology
Website
primemedicine.com

PRME key statistics

Market cap
711.00M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.11M
Volume
3.69M
Open price
$3.75
High today
$4.05
Low today
$3.73
52 Week high
$6.30
52 Week low
$2.67

Prime Medicine (PRME) at a glance

As of Oct 20, 2026, Prime Medicine (PRME) shares are priced at $3.92, giving the company a market cap of 711.00M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.73 and $4.05. The current price is 5.1% above the day's low and 3.2% below its high.

Volume so far is 3.69M shares, below the average of 5.11M shares a day.

Over the past year Prime Medicine has ranged from $2.67 to $6.30, and now sits 34% of the way up that range.

Prime Medicine met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.24 per share against an estimate of -$0.2625.

The average analyst price target is $7.26, 85.1% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

86%of 7 analyst ratings say Buy
  • Buy85.7%
  • Hold14.3%
  • Sell0.0%
Price target · 13 analystsAvg $7.26
Low
$4.29
Now
$3.92
High
$11.55

PRME earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 15.5% on average.

  1. Q3 FY24: reported -$0.44 per share against an estimate of -$0.4031
  2. Q4 FY24: reported -$0.31 per share against an estimate of -$0.3998
  3. Q1 FY25: reported -$0.40 per share against an estimate of -$0.3265
  4. Q2 FY25: reported -$0.41 per share against an estimate of -$0.3709
  5. Q3 FY25: reported -$0.32 per share against an estimate of -$0.2581
  6. Q4 FY25: reported -$0.26 per share against an estimate of -$0.2564
  7. Q1 FY26: reported -$0.28 per share against an estimate of -$0.2554
  8. Q2 FY26: reported -$0.24 per share against an estimate of -$0.2625

PRME news

  • Avi Kapoor

    Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday

  • Vandana Singh

    Prime Medicine Gets FDA Green Light for Gene Editing Study

  • Avi Kapoor

    Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    Prime Medicine to Participate in Upcoming Investor Conferences

  • Vandana Singh

    Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case

  • Press releaseGlobe Newswire

    Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference

  • Press releaseGlobe Newswire

    Prime Medicine to Present at Jefferies Global Healthcare Conference

  • Press releasePRNewswire

    The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

Similar companies

Companies in the same industry as Prime Medicine

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.